Table 1.
Expression of granulysin in haematological neoplasms
| Lymphoma/leukaemia entity | n/N (%) | |
|---|---|---|
| B cell lymphoma | Chronic lymphocytic leukaemia | 0/10 |
| Mantle cell lymphoma | 0/10 | |
| Follicular lymphoma | 0/10 | |
| Diffuse large B cell lymphoma | 0/10 | |
| T-cell/histiocyte-rich large B cell lymphoma | 0/7 | |
| Burkitt lymphoma | 0/9 | |
| Hairy cell leukaemia | 0/7 | |
| Chronic active EBV infection (CAEBV), B cell type | 0/1 | |
| T/NK cell lymphoma | Extranodal NK/T cell lymphoma, nasal type | 61/86 (71%) |
| ALK-negative anaplastic large cell lymphoma (ALK-ALCL) | 4/15 (26%) | |
| Enteropathy-associated T-cell lymphoma (EATL) | 1/8 (12%) | |
| Peripheral T-cell lymphoma, NOS (PTCL, NOS) | 2/50 (4%) | |
| T-cell large granular lymphocytic leukaemia | 0/8 | |
| Angioimmunoblastic T-cell lymphoma | 0/24 | |
| ALK-positive anaplastic large cell lymphoma (ALK+ALCL) | 0/5 | |
| Hepatosplenic T-cell lymphoma | 0/8 | |
| T-lymphoblastic leukaemia (T-ALL) | 0/6 | |
| Adult T cell leukaemia/lymphoma (ATLL) | 0/6 | |
| CAEBV, T cell type | 0/4 | |
| Hodgkin lymphoma | Classical | 0/20 |
| Lymphocyte predominant | 0/29 | |
| Plasma cells neoplasms | Myeloma | 0/10 |
n number of cases positive for granulysin, N total number of cases, % percentage of positive cases, NOS not otherwise specified